重大事件
外國發行人報告
6-K
2026-07-23
Innate Pharma 將於BTIG虛擬大會探討膀胱癌治療，聚焦Nectin-4 ADC候選藥物
AI 繁中摘要
Innate Pharma 申報 6-K 文件，公告將參與 BTIG 虛擬生物技術大會的膀胱癌專題討論環節 🧬
這份申報文件為外國私人發行人提交的 6-K 表格，由總部位於法國的臨床階段生物科技公司 Innate Pharma SA（Euronext: IPH; Nasdaq: IPHA）於 2026 年 7 月 23 日發布。
重點事件：
- Innate Pharma 的執行副總裁兼首席醫學官 Sonia Quaratino 將於 2026 年 7 月 28 日美國東部時間上午 10:30 / 中歐時間下午 4:30，在 BTIG 虛擬生物技術大會上參與題為「膀胱癌治療格局的轉變」的小組討論。
- 此次參與凸顯公司對泌尿系統腫瘤領域的關注，尤其是其管線中的候選藥物 IPH4502（一款差異化的 Nectin-4 ADC），正針對實體瘤（包括膀胱癌）進行開發。
公司概覽：
- Innate Pharma 是一家全球臨床階段生物技術公司，專注於開發癌症免疫療法。
- 其產品組合包括：IPH4502（Nectin-4 ADC）、lacutamab（抗 KIR3DL2 抗體，用於皮膚 T 細胞淋巴瘤）以及 monalizumab（抗 NKG2A 抗體，與阿斯利康合作開發非小細胞肺癌）。
- 公司與賽諾菲、阿斯利康等頂尖藥廠及學術機構保持合作。
- 總部位於法國馬賽，美國辦公室設在馬里蘭州洛克維爾，於泛歐交易所及納斯達克雙重上市。
前瞻性陳述與風險提示：
- 新聞稿包含前瞻性陳述，實際結果可能因多種風險因素而異，詳情請參閱向 AMF 及 SEC 提交的公開文件（包括 2025 年 12 月 31 日止年度的 20-F 年報）。
對投資者的潛在影響：
- 雖然此次僅為會議出席，未有重大財務數據公布，但管理層在頂尖產業會議上發聲，有助提升公司在膀胱癌免疫治療領域的能見度，並可能預示未來管線數據更新或合作動向。投資者應關注後續臨床進展及監管溝通。
展開英文正文
EX-99.1 2 a260723exhibit991.htm EX-99.1 Document EXHIBIT 99.1 Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference Marseille, France, July 23, 2026, 7:00 AM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel discussion, Changing Treatment Landscape in Bladder Cancer, at the BTIG Virtual Biotechnology Conference. BTIG Virtual Biotechnology Conference 2026 Panel discussion: Changing Treatment Landscape in Bladder Cancer Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC). Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. Information about Innate Pharma shares ISIN codeTicker codeLEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. For more information Investors & Media Relations Innate Pharma Stéphanie Cornen [email protected] Investor Relations [email protected] Media [email protected]